achieved FDA approval for Cabenuva, a monthly injectable antiretroviral regimen to treat HIV.The monthly injections were touted for their ability to reduce treatment for the virus from a daily pill regimen to just 12 treatment days per year.Now, ViiV has announced that Cabenuva — a combination of two antiretrovirals, Viiv’s cabotegravir and Johnson & Johnson’s rilpivirine — can achieve similar levels of performance when administered every two months.“It provides an option that could change the treatment experience for some people living with HIV by removing the need for daily pills for the treatment of HIV,” Hans Jäeger, MD, investigator for Viiv’s ATLAS-2M study, said in a statement.“Taking a pill every day can come as an unwelcome daily.
Read more on metroweekly.com